ThromboGenics Appoints Dominique Vanfleteren as new Chief Financial Officer
ThromboGenics NV has appointed Dominique Vanfleteren as its new Chief Financial Officer with immediate effect.
Dominique has over 25 years of experience in senior finance, operational, control and reporting roles within quoted international biopharmaceutical companies.
Before joining ThromboGenics, he spent 12 years at UCB where he held a number of international managerial finance positions, the latest being the CFO of UCB’s Asia Pacific Operations, operating from Brussels and Shanghai.
Prior to joining UCB, Dominique worked for GSK during 16 years.